ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dixon, I. M.C.
Right arrow Articles by Raizman, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dixon, I. M.C.
Right arrow Articles by Raizman, J. E.
Related Collections
Right arrow Myocardial infarction

Ann Thorac Surg 2005;79:1337
© 2005 The Society of Thoracic Surgeons

Original articles: Cardiovascular

INVITED COMMENTARY

Ian M.C. Dixon, PhD, Josh E. Raizman, BSc

Department of Physiology, University of Manitoba, Room 3038, SBGH Research Centre, 351 Tache Avenue, Winnipeg, MB R2H 2A6, Canada idixon@sbrc.cajraizman@sbrc.ca

The first 20% of the full text of this article appears below.

The dogma with respect to apoptosis and the biological fate of cardiac myocytes implicates the eventual death of those cells. Graded, suspended, or reversible apoptosis is a relatively unexplored entity in the setting of heart failure or cardiomyopathy. If cells that are expressing apoptotic genes (eg, caspase-3) could be "rescued" or recruited back into the functional myocardium using selective gene therapy emphasizing expression of genes . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.